Developer docs
API playgroundTry for free, no card

Search company profiles

Pixyl

Full company profile

uuid0002u4e

Namestring
Pixyl
Legal namestring
Pixyl SAS
Websiteurl
pixyl.ai
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Pixyl SAS is a France-based (La Tronche) medical imaging AI company that develops proprietary computer-vision algorithms for automated analysis of brain MRI scans, primarily targeting neuroinflammatory and neurodegenerative disorders. The company's flagship platform, Pixyl.Neuro, comprises specialized modules — Pixyl.Neuro.MS for multiple sclerosis lesion segmentation and quantification, and Pixyl.Neuro.BV for brain volumetry — and is delivered as a regulated medical device: FDA 510(k)-cleared (Class II) and CE-marked Class IIa under EU MDR. Reported clinical performance includes up to 28% enhanced T2-FLAIR lesion detection versus unaided reads and up to 65% reduction in reading time, with analysis completed in under five minutes on minimal MR protocols; validation is anchored in peer-reviewed publications in Journal of Neuroradiology and collaborations with academic consortia (PRIMUS, ANR-funded) and GE Healthcare (AI DReAM).

Pixyl monetizes through enterprise licensing of its regulated AI software to hospital radiology and neurology departments, integrating into existing PACS/radiology workflows via a subscription model with quote-based pricing typical of Class II medical device software. The company's GTM is anchored in scientific publication, academic collaboration, and clinical validation rather than broad-based marketing, and customer reach is concentrated in healthcare-provider segments (radiology departments, neurologists, MS specialists, academic research centers). In 2025 Pixyl was acquired by French AI radiology peer Gleamer as part of a consolidation strategy, and in March 2026 Gleamer (including Pixyl) was itself acquired by US imaging group RadNet for €230 million, positioning Pixyl as RadNet's European AI hub for neurological imaging within the DeepHealth unit.

At the time of the RadNet transaction, the parent Gleamer business reported approximately €30 million ARR across roughly 700 clients in 44 countries, but no Pixyl-specific revenue, headcount, or unit economics have been disclosed. Prior to the Gleamer acquisition, Pixyl had raised approximately $3.3 million in disclosed funding (notably a 2021 round with Bpifrance, Elaia, and Holnest) and operated with 11–50 employees, indicating a focused R&D and clinical-validation stage rather than a scaled commercial operation.

Short descriptiontext

Pixyl is a French AI medical-device company that provides FDA-cleared and CE-marked software for automated brain MRI analysis, focused on multiple sclerosis lesion detection, brain volumetry, and longitudinal monitoring for radiology and neurology departments.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLa Tronche, France
HQ citystring
La Tronche
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI brain MRI analysis, medical imaging software, multiple sclerosis detection, brain volumetry tools, radiology AI platform
Industry2 codes
PRIMARYHLACANAM
DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLAAANAJ
Real-World Evidence (RWE) & Outcomes Analytics for Precision Therapies
NAICS code1 code
  • Medical Laboratories621511
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Medical Imaging AI Software
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1AI Medical Imaging Software Licensing
TypeSubscription Recurring
Description

Pixyl generates revenue through licensing its AI-powered MRI analysis software as a medical device. Given the regulatory clearances (FDA, CE-mark) and B2B nature, the model likely involves annual subscription contracts with healthcare institutions.

pixyl.ai
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1Pixyl.Neuro
Description

AI-powered solution for brain MRI analysis detecting anomalies for neuroinflammatory and neurodegenerative disorders, with FDA clearance and CE-mark certification.

pixyl.ai
+2 more records
Core offering1 text field

Pixyl develops and sells Pixyl.Neuro, an FDA-cleared class II and CE-marked class IIa AI medical device that performs automated brain MRI analysis for neuroinflammatory and neurodegenerative disorders, with a focus on multiple sclerosis. The software detects lesions, quantifies brain volumes, and produces structured diagnostic reports in under five minutes, integrating into existing radiology workflows. Pixyl also develops the PRIMUS research platform, a precision-medicine project combining AI lesion segmentation with clinical decision support for MS treatment selection.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Up to 28% Enhanced Detection Rate for T2-FLAIR lesion detection and evolution
+2 more records
Product overview1 text field

Pixyl is an AI radiology company focused on augmented MRI analysis for improved patient care. Now a Gleamer company, Pixyl's portfolio centers on Pixyl.Neuro, a unified AI platform for brain MRI analysis comprising specialized modules: Pixyl.Neuro.MS for multiple sclerosis diagnosis and follow-up, and Pixyl.Neuro.BV for brain volumetry. Pixyl.Neuro is certified as an FDA-cleared class II and CE-marked class IIa medical device under EU MDR, leveraging proprietary AI algorithms to deliver clinically actionable brain MRI insights in under five minutes.

Product and service2 records
1Pixyl.Neuro
CategoryMedical Imaging AI Software
Description

AI-powered brain MRI analysis platform that detects anomalies and quantifies brain structures for neuroinflammatory and neurodegenerative disorders, providing automated lesion segmentation, brain volumetry, and structured diagnostic reports in under five minutes. FDA-cleared class II and CE-marked class IIa medical device under EU MDR, sold to radiology and neurology departments via enterprise licensing.

2PRIMUS (PRojections In MUltiple Sclerosis)
CategoryClinical Research Platform
Description

Precision-medicine research platform for multiple sclerosis combining a brain MRI viewer with AI-powered lesion segmentation and a clinical decision support system for treatment selection based on similar-patient data. Led by an academic-IT-pharmaceutical consortium and supported by the French National Research Agency under reference ANR-21-RHUS-0014 as part of the France 2030 plan, targeting academic medical centers and research institutions.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1Gleamer
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Gleamer acquired Pixyl in 2025 as part of its consolidation strategy to expand into brain MRI analysis. Pixyl operates as Gleamer's European AI hub for neurological imaging solutions, with solutions including Pixyl.Neuro and Gleamer Copilot integrated into the portfolio.

pixyl.ai
2French National Research Agency (ANR)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

ANR supports the PRIMUS (PRojections In MUltiple Sclerosis) precision medicine platform project as part of France 2030 plan under reference ANR-21-RHUS-0014. PRIMUS aims to provide neurologists and neuroradiologists with AI-powered tools for MS care pathway support, including brain MRI lesion segmentation and clinical decision support.

pixyl.ai
Strategic tierCoreTypeTechnology or Integration
Description

Collaboration on AI DReAM (AI Diagnostic Research for Accelerated Medicine) initiative, a research project combining Pixyl's brain MRI AI expertise with GE Healthcare's imaging technology platform for advancing diagnostic capabilities.

4Rennes University Hospital
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Lead clinical partner for PRIMUS platform development. Rennes University Hospital provides official project description and serves as the primary clinical research site for validating MS precision medicine tools.

pixyl.ai
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1icometrix
TypeDirect peer
Description

Belgium-based AI company with FDA-cleared icobrain platform for brain MRI quantification in MS, dementia, and traumatic brain injury. Most direct head-to-head competitor to Pixyl.Neuro.MS in the MS and brain volumetry space.

TypeDirect peer
Description

Developer of NeuroQuant, a long-established FDA-cleared brain MRI volumetric analysis tool widely used in clinical and research settings. Directly comparable to Pixyl.Neuro.BV for hippocampus, amygdala, and subcortical volumetry.

TypeBroad incumbent
Description

One of the largest AI radiology platforms covering CT and MRI across multiple anatomies and pathologies including neuro. Competes with Pixyl for hospital-wide radiology AI budgets, though Aidoc is broader and less specialized in MS/brain volumetry.

TypeBroad incumbent
Description

Enterprise radiology AI platform with strong neurology focus (stroke detection, care coordination). Larger and broader than Pixyl but overlaps in the neuroimaging category and competes for the same hospital procurement budgets.

TypeBroad incumbent
Description

India-based radiology AI company with FDA-cleared products across chest, head CT, and musculoskeletal imaging. Competes with Pixyl in enterprise sales to multi-site hospital networks seeking consolidated AI platforms.

TypeDirect peer
Description

Spain-based AI radiology company with a strong neuroimaging and whole-body imaging focus, including quantitative MRI biomarkers. Directly comparable to Pixyl in applying AI to brain MRI analysis for clinical and research use.

TypeBroad incumbent
Description

Medical imaging AI platform primarily focused on neurovascular and stroke imaging with enterprise hospital deployments. Competes for the same neurology imaging budgets as Pixyl and represents a broader-platform alternative.

TypeOthers
Description

Former competitor in AI radiology now Pixyl's parent company (since 2025) and central distribution platform. Included as a peer because it absorbed Pixyl's offering into its portfolio and jointly addresses the radiology AI market.

TypeBroad incumbent
Description

Cloud-native radiology AI platform with FDA-cleared products across cardiac and oncologic imaging. Operates in adjacent enterprise radiology AI category and competes for the same hospital imaging IT consolidation budgets.

TypeDirect peer
Description

AI imaging analysis company with FDA-cleared lung and chest CT analysis tools expanding into broader radiology AI workflows. Comparable as a similarly sized medical imaging AI specialist with regulatory clearances and enterprise sales motion.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability3 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pixyl

Medical Imaging AI Softwarepixyl.ai

Pixyl is a French AI medical-device company that provides FDA-cleared and CE-marked software for automated brain MRI analysis, focused on multiple sclerosis lesion detection, brain volumetry, and longitudinal monitoring for radiology and neurology departments.

What Pixyl does

Pixyl SAS is a France-based (La Tronche) medical imaging AI company that develops proprietary computer-vision algorithms for automated analysis of brain MRI scans, primarily targeting neuroinflammatory and neurodegenerative disorders. The company's flagship platform, Pixyl.Neuro, comprises specialized modules — Pixyl.Neuro.MS for multiple sclerosis lesion segmentation and quantification, and Pixyl.Neuro.BV for brain volumetry — and is delivered as a regulated medical device: FDA 510(k)-cleared (Class II) and CE-marked Class IIa under EU MDR. Reported clinical performance includes up to 28% enhanced T2-FLAIR lesion detection versus unaided reads and up to 65% reduction in reading time, with analysis completed in under five minutes on minimal MR protocols; validation is anchored in peer-reviewed publications in Journal of Neuroradiology and collaborations with academic consortia (PRIMUS, ANR-funded) and GE Healthcare (AI DReAM).

Pixyl monetizes through enterprise licensing of its regulated AI software to hospital radiology and neurology departments, integrating into existing PACS/radiology workflows via a subscription model with quote-based pricing typical of Class II medical device software. The company's GTM is anchored in scientific publication, academic collaboration, and clinical validation rather than broad-based marketing, and customer reach is concentrated in healthcare-provider segments (radiology departments, neurologists, MS specialists, academic research centers). In 2025 Pixyl was acquired by French AI radiology peer Gleamer as part of a consolidation strategy, and in March 2026 Gleamer (including Pixyl) was itself acquired by US imaging group RadNet for €230 million, positioning Pixyl as RadNet's European AI hub for neurological imaging within the DeepHealth unit.

At the time of the RadNet transaction, the parent Gleamer business reported approximately €30 million ARR across roughly 700 clients in 44 countries, but no Pixyl-specific revenue, headcount, or unit economics have been disclosed. Prior to the Gleamer acquisition, Pixyl had raised approximately $3.3 million in disclosed funding (notably a 2021 round with Bpifrance, Elaia, and Holnest) and operated with 11–50 employees, indicating a focused R&D and clinical-validation stage rather than a scaled commercial operation.

Pixyl firmographics

Firmographics
Name
Pixyl
Legal name
Pixyl SAS
Website
https://pixyl.ai
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Pixyl is a French AI medical-device company that provides FDA-cleared and CE-marked software for automated brain MRI analysis, focused on multiple sclerosis lesion detection, brain volumetry, and longitudinal monitoring for radiology and neurology departments.
Ownership category
akta.pro rank

Pixyl industry classification

Industry
Product category
Medical Imaging AI Software
NAICS
Medical Laboratories (621511)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLACANAM
DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHLAAANAJ
Real-World Evidence (RWE) & Outcomes Analytics for Precision Therapies

Keywords

  • AI brain MRI analysis
  • Medical imaging software
  • Multiple sclerosis detection
  • Brain volumetry tools
  • Radiology AI platform

Where Pixyl is headquartered

Location

Headquarters

HQ city
La Tronche
HQ country
France
HQ region
Europe

Offices1 record

Markets served

Pixyl business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. AI Medical Imaging Software Licensing: Pixyl generates revenue through licensing its AI-powered MRI analysis software as a medical device. Given the regulatory clearances (FDA, CE-mark) and B2B nature, the model likely involves annual subscription contracts with healthcare institutions.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Pixyl product offering

Product offering

Core offering

Pixyl develops and sells Pixyl.Neuro, an FDA-cleared class II and CE-marked class IIa AI medical device that performs automated brain MRI analysis for neuroinflammatory and neurodegenerative disorders, with a focus on multiple sclerosis. The software detects lesions, quantifies brain volumes, and produces structured diagnostic reports in under five minutes, integrating into existing radiology workflows. Pixyl also develops the PRIMUS research platform, a precision-medicine project combining AI lesion segmentation with clinical decision support for MS treatment selection.

Product overview

Pixyl is an AI radiology company focused on augmented MRI analysis for improved patient care. Now a Gleamer company, Pixyl's portfolio centers on Pixyl.Neuro, a unified AI platform for brain MRI analysis comprising specialized modules: Pixyl.Neuro.MS for multiple sclerosis diagnosis and follow-up, and Pixyl.Neuro.BV for brain volumetry. Pixyl.Neuro is certified as an FDA-cleared class II and CE-marked class IIa medical device under EU MDR, leveraging proprietary AI algorithms to deliver clinically actionable brain MRI insights in under five minutes.

Differentiator

Problem solved

Functional benefit

Brands

  • Pixyl.Neuro: AI-powered solution for brain MRI analysis detecting anomalies for neuroinflammatory and neurodegenerative disorders, with FDA clearance and CE-mark certification.
  • Pixyl.Neuro.MS
  • Pixyl.Neuro.BV

Products and services

  • Pixyl.Neuro AI-powered brain MRI analysis platform that detects anomalies and quantifies brain structures for neuroinflammatory and neurodegenerative disorders, providing automated lesion segmentation, brain volumetry, and structured diagnostic reports in under five minutes. FDA-cleared class II and CE-marked class IIa medical device under EU MDR, sold to radiology and neurology departments via enterprise licensing.
  • PRIMUS (PRojections In MUltiple Sclerosis) Precision-medicine research platform for multiple sclerosis combining a brain MRI viewer with AI-powered lesion segmentation and a clinical decision support system for treatment selection based on similar-patient data. Led by an academic-IT-pharmaceutical consortium and supported by the French National Research Agency under reference ANR-21-RHUS-0014 as part of the France 2030 plan, targeting academic medical centers and research institutions.

Quantifiable outcome

  • Up to 28% Enhanced Detection Rate for T2-FLAIR lesion detection and evolution
  • +2 more outcomes

Companies that use Pixyl

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Pixyl technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Pixyl partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • GleamercoreStrategic or Co-development Partner · 1 January 2025Gleamer acquired Pixyl in 2025 as part of its consolidation strategy to expand into brain MRI analysis. Pixyl operates as Gleamer's European AI hub for neurological imaging solutions, with solutions including Pixyl.Neuro and Gleamer Copilot integrated into the portfolio.
  • French National Research Agency (ANR)coreStrategic or Co-development PartnerANR supports the PRIMUS (PRojections In MUltiple Sclerosis) precision medicine platform project as part of France 2030 plan under reference ANR-21-RHUS-0014. PRIMUS aims to provide neurologists and neuroradiologists with AI-powered tools for MS care pathway support, including brain MRI lesion segmentation and clinical decision support.
  • GE HealthcarecoreTechnology or IntegrationCollaboration on AI DReAM (AI Diagnostic Research for Accelerated Medicine) initiative, a research project combining Pixyl's brain MRI AI expertise with GE Healthcare's imaging technology platform for advancing diagnostic capabilities.
  • Rennes University HospitalcoreStrategic or Co-development PartnerLead clinical partner for PRIMUS platform development. Rennes University Hospital provides official project description and serves as the primary clinical research site for validating MS precision medicine tools.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Pixyl competitors and assessment

Company assessment

Direct peers

  • icometrix: Belgium-based AI company with FDA-cleared icobrain platform for brain MRI quantification in MS, dementia, and traumatic brain injury. Most direct head-to-head competitor to Pixyl.Neuro.MS in the MS and brain volumetry space.
  • Cortechs.ai: Developer of NeuroQuant, a long-established FDA-cleared brain MRI volumetric analysis tool widely used in clinical and research settings. Directly comparable to Pixyl.Neuro.BV for hippocampus, amygdala, and subcortical volumetry.
  • Quibim: Spain-based AI radiology company with a strong neuroimaging and whole-body imaging focus, including quantitative MRI biomarkers. Directly comparable to Pixyl in applying AI to brain MRI analysis for clinical and research use.
  • Imbio: AI imaging analysis company with FDA-cleared lung and chest CT analysis tools expanding into broader radiology AI workflows. Comparable as a similarly sized medical imaging AI specialist with regulatory clearances and enterprise sales motion.

Broad incumbents

  • Aidoc: One of the largest AI radiology platforms covering CT and MRI across multiple anatomies and pathologies including neuro. Competes with Pixyl for hospital-wide radiology AI budgets, though Aidoc is broader and less specialized in MS/brain volumetry.
  • Viz.ai: Enterprise radiology AI platform with strong neurology focus (stroke detection, care coordination). Larger and broader than Pixyl but overlaps in the neuroimaging category and competes for the same hospital procurement budgets.
  • Qure.ai: India-based radiology AI company with FDA-cleared products across chest, head CT, and musculoskeletal imaging. Competes with Pixyl in enterprise sales to multi-site hospital networks seeking consolidated AI platforms.
  • RapidAI: Medical imaging AI platform primarily focused on neurovascular and stroke imaging with enterprise hospital deployments. Competes for the same neurology imaging budgets as Pixyl and represents a broader-platform alternative.
  • Arterys: Cloud-native radiology AI platform with FDA-cleared products across cardiac and oncologic imaging. Operates in adjacent enterprise radiology AI category and competes for the same hospital imaging IT consolidation budgets.

Others

  • Gleamer: Former competitor in AI radiology now Pixyl's parent company (since 2025) and central distribution platform. Included as a peer because it absorbed Pixyl's offering into its portfolio and jointly addresses the radiology AI market.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Pixyl social profiles

Digital presence

Pixyl compliance and trust

Trust signal

Compliance2 records

Pixyl financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pixyl leadership team

Management profile

Number of profiles

Profiles3 records

Pixyl funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pixyl M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pixyl

What does Pixyl do?

Pixyl develops and sells Pixyl.Neuro, an FDA-cleared class II and CE-marked class IIa AI medical device that performs automated brain MRI analysis for neuroinflammatory and neurodegenerative disorders, with a focus on multiple sclerosis. The software detects lesions, quantifies brain volumes, and produces structured diagnostic reports in under five minutes, integrating into existing radiology workflows. Pixyl also develops the PRIMUS research platform, a precision-medicine project combining AI lesion segmentation with clinical decision support for MS treatment selection.

Is Pixyl a public or private company?

Pixyl is a private company. It is classified as corporate owned and is currently operating.

When was Pixyl founded?

Pixyl was founded in 2015. It employs 11 to 50 people.

Where is Pixyl based?

Pixyl is headquartered in La Tronche, France, in the Europe region.

How does Pixyl make money?

One revenue line is on record: AI Medical Imaging Software Licensing.

Who are Pixyl's main competitors?

Direct peers on record are icometrix, Cortechs.ai, Quibim and Imbio. Broad incumbents are Aidoc, Viz.ai, Qure.ai, RapidAI and Arterys. Gleamer is listed as an others.

Does Pixyl have an API?

No public API is recorded for Pixyl.

What industry is Pixyl in?

Pixyl's product category is Medical Imaging AI Software. Its primary akta.pro industry code is HLACANAM, DTx/SaMD Evidence, Outcomes & Real-World Data (RWE) Platforms, with a secondary code of HLAAANAJ, Real-World Evidence (RWE) & Outcomes Analytics for Precision Therapies. Its NAICS code is 621511 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FrtExpanding Frontiers: Medical Imaging AI M&A OpportunitiesThe medical imaging AI sector is experiencing a surge in M&A activity, with strategic players like Gleamer acquiring early-stage startups such as Pixyl and Caerus Medical to consolidate niche capabilities. This trend is driven by market fragmentation, radiologist shortages, and the high value of regulatory approvals, creating exit opportunities for companies with modest revenues but strong FDA or CE clearances.Tech.euGleamer acquires Pixyl and Caerus Medical: a leap forward in AI-driven radiologyGleamer acquired Pixyl and Caerus Medical, adding FDA- and CE-cleared MRI AI solutions to its portfolio. The acquisitions cover neuro and lumbar spine MRI, expanding Gleamer's offerings across X-ray, mammography, CT, and MRI. The move positions Gleamer with a proprietary suite of AI-driven imaging tools.GlobeNewswireBlackford and Pixyl Partner to Aid Detection and Monitoring of Neurological DiseasesBlackford and Pixyl announced a commercial partnership to integrate Pixyl.Neuro, an AI software for brain MRI analysis, into Blackford's platform. The solution demonstrates enhanced detection rates up to 28% and has received FDA 510(k) and CE-mark class IIa certification. The partnership aims to support diagnosis and monitoring of neuroinflammatory and neurodegenerative diseases.TmcnetBlackford and Pixyl Partner to Aid Detection and Monitoring of Neurological DiseasesBlackford and Pixyl announced a commercial partnership to integrate Pixyl.Neuro, an AI software for brain MRI analysis, into Blackford's platform. The solution demonstrates enhanced detection rates up to 28% and has received FDA 510(k) and CE-mark class IIa certification.GlobeNewswireBlackford and Pixyl Partner to Aid Detection and Monitoring of Neurological DiseasesBlackford and Pixyl announced a commercial partnership to integrate Pixyl.Neuro, an AI software for brain MRI analysis, into Blackford's platform. The solution demonstrates enhanced detection rates up to 28% and has received FDA 510(k) and CE-mark class IIa certification.PR NewswireBrainomix announces new partnership with Pixyl to expand its offering with multiple sclerosis solutionBrainomix, an Oxford-based AI medtech company, announced a partnership with Grenoble-based Pixyl to exclusively distribute Pixyl's Neuro.MS SaaS solution across the UK, Ireland, the Nordics, and key Eastern European markets. The AI-powered software automatically analyzes brain MRI images to identify and quantify multiple sclerosis abnormalities, including lesion volume and brain atrophy, in under five minutes. The collaboration allows Brainomix to expand beyond its e-Stroke platform into neurology imaging, while Pixyl gains access to Brainomix's established customer base and sales infrastructure to accelerate adoption of its technology.FRENCHWEB.FRImagerie médicale: le Français Pixyl lève 2,2 millions d’euros auprès d’ElaiaFrench medical imaging startup Pixyl has raised 2.2 million euros in funding from Elaia, with participation from Holnest and Bpifrance, to accelerate the launch of its AI-based neuroimaging solution on the European market. The company, which already holds CE marking for its Pixyl.Neuro software, plans to seek FDA authorization to expand into the United States.